Raf Magar

573 total citations
21 papers, 457 citations indexed

About

Raf Magar is a scholar working on Neurology, Surgery and Epidemiology. According to data from OpenAlex, Raf Magar has authored 21 papers receiving a total of 457 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Neurology, 4 papers in Surgery and 4 papers in Epidemiology. Recurrent topics in Raf Magar's work include Botulinum Toxin and Related Neurological Disorders (7 papers), Neurological disorders and treatments (5 papers) and Gastrointestinal motility and disorders (3 papers). Raf Magar is often cited by papers focused on Botulinum Toxin and Related Neurological Disorders (7 papers), Neurological disorders and treatments (5 papers) and Gastrointestinal motility and disorders (3 papers). Raf Magar collaborates with scholars based in United States, United Kingdom and Switzerland. Raf Magar's co-authors include Albert Marchetti, Helen Lau, Allen B. King, Patrick J. Boyle, John P. Martin, Leann Olansky, Zvezdan Pirtošek, Jarosław Sławek, Jan Larsen and Leslie J. Findley and has published in prestigious journals such as Neurology, Movement Disorders and Toxicon.

In The Last Decade

Raf Magar

20 papers receiving 432 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Raf Magar United States 9 153 109 86 71 70 21 457
Szu‐Ju Chen Taiwan 10 102 0.7× 75 0.7× 32 0.4× 33 0.5× 19 0.3× 25 282
L. Ø. Dolva Norway 11 51 0.3× 68 0.6× 66 0.8× 70 1.0× 57 0.8× 20 355
Robert M. Audet Canada 10 64 0.4× 92 0.8× 11 0.1× 88 1.2× 51 0.7× 16 385
N. Sayre United States 11 38 0.2× 137 1.3× 53 0.6× 48 0.7× 12 0.2× 18 386
J. Schaefer Germany 8 34 0.2× 207 1.9× 26 0.3× 34 0.5× 43 0.6× 22 389
Tinisha L. Mayo United States 5 138 0.9× 61 0.6× 38 0.4× 40 0.6× 16 0.2× 5 326
F. A. M. Baumeister Germany 11 28 0.2× 203 1.9× 41 0.5× 15 0.2× 54 0.8× 27 528
Sebahattin Vurucu Türkiye 11 29 0.2× 50 0.5× 41 0.5× 17 0.2× 51 0.7× 29 323
Sachiko Hara Japan 9 73 0.5× 59 0.5× 29 0.3× 140 2.0× 10 0.1× 16 437
Jens‐Otto Andreas Germany 11 106 0.7× 38 0.3× 32 0.4× 54 0.8× 20 0.3× 18 458

Countries citing papers authored by Raf Magar

Since Specialization
Citations

This map shows the geographic impact of Raf Magar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raf Magar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raf Magar more than expected).

Fields of papers citing papers by Raf Magar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raf Magar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raf Magar. The network helps show where Raf Magar may publish in the future.

Co-authorship network of co-authors of Raf Magar

This figure shows the co-authorship network connecting the top 25 collaborators of Raf Magar. A scholar is included among the top collaborators of Raf Magar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raf Magar. Raf Magar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bernstein, Jonathan A., Christopher J. Tyson, Anurag Relan, Philippe Adams, & Raf Magar. (2019). Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema Attacks. Journal of Managed Care & Specialty Pharmacy. 26(2). 203–210. 4 indexed citations
2.
Pimentel, Mark, et al.. (2016). A Predictive Model to Estimate Cost Savings of a Novel Diagnostic Blood Panel for Diagnosis of Diarrhea-predominant Irritable Bowel Syndrome. Clinical Therapeutics. 38(7). 1638–1652.e9. 6 indexed citations
3.
4.
Pimentel, Mark, et al.. (2015). Inclusion Of A Novel Ibs Blood Panel For Diagnosing Diarrhea Predominant Irritable Bowel Syndrome (Ibs-D): A Uk Perspective. Value in Health. 18(7). A350–A350. 3 indexed citations
5.
6.
Blumenfeld, Andrew, et al.. (2014). The Durability of OnabotulinumtoxinA for the Treatment of Chronic Migraine: CLARITY Pilot Study (P7.186). Neurology. 82(10_supplement). 1 indexed citations
7.
8.
9.
Blumenfeld, Andrew, et al.. (2014). 30. The durability of onabotulinumtoxinA for the treatment of chronic migraine: CLARITY Pilot Study. Toxicon. 93. S11–S11. 2 indexed citations
10.
Magar, Raf, et al.. (2010). Performance of okra in relation to yellow vein mosaic virus in different seasons.. International Journal of Plant Sciences Muzaffarnagar. 5(1). 33–35. 3 indexed citations
11.
Magar, Raf, et al.. (2009). Genetic variability, correlations and path co-efficient analysis in okra [Abelmoschus esculentus (L.) Moench].. International Journal of Plant Sciences Muzaffarnagar. 4(2). 498–501. 7 indexed citations
12.
Marchetti, Albert, Raf Magar, Leslie J. Findley, et al.. (2005). Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study. Movement Disorders. 20(8). 937–944. 83 indexed citations
13.
Brashear, Allison, et al.. (2005). Longitudinal assessment of the dose consistency of botulinum toxin type a (BOTOX®) for cervical dystonia. Advances in Therapy. 22(1). 49–55. 22 indexed citations
14.
15.
Boyle, Patrick J., Allen B. King, Leann Olansky, et al.. (2002). Effects of Pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records. Clinical Therapeutics. 24(3). 378–396. 140 indexed citations
16.
Marchetti, Albert, Raf Magar, Helen Lau, et al.. (2001). Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clinical Therapeutics. 23(11). 1904–1921. 33 indexed citations
17.
Marchetti, Albert, Liping Wang, Raf Magar, et al.. (2000). Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: Cost implications of a clinical trial for valrubicin. Clinical Therapeutics. 22(4). 422–438. 16 indexed citations
18.
Brashear, Allison, et al.. (2000). Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review. Clinical Therapeutics. 22(12). 1516–1524. 38 indexed citations
19.
Marchetti, Albert, et al.. (1999). Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: Potential for savings. Clinical Therapeutics. 21(4). 752–766. 51 indexed citations
20.
Marchetti, Albert, Raf Magar, James H. Fischer, Edward P. Sloan, & P Fischer. (1996). A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx®) versus intravenous phenytoin (Dilantin®) in hospital emergency departments. Clinical Therapeutics. 18(5). 953–966. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Szu‐Ju Chen Breakdown of academic impact, for papers by L. Ø. Dolva Breakdown of academic impact, for papers by Robert M. Audet Breakdown of academic impact, for papers by N. Sayre Breakdown of academic impact, for papers by J. Schaefer Breakdown of academic impact, for papers by Tinisha L. Mayo Breakdown of academic impact, for papers by F. A. M. Baumeister Breakdown of academic impact, for papers by Sebahattin Vurucu Breakdown of academic impact, for papers by Sachiko Hara Breakdown of academic impact, for papers by Jens‐Otto Andreas
Rankless by CCL
2026